Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells.
about
Micro and nanoparticle drug delivery systems for preventing allotransplant rejectionEffect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young RatsHand transplants and the mandate for tolerance.Engineering biomimetic materials for islet transplantationEngineering an "infectious" T(reg) biomimetic through chemoselective tethering of TGF-β1 to PEG brush surfaces.Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Bioinspired controlled release of CCL22 recruits regulatory T cells in vivoBiomaterial Strategies for Immunomodulation.All-trans retinoic acid and rapamycin synergize with transforming growth factor-β1 to induce regulatory T cells but confer different migratory capacitiesPrevention of inflammation-mediated bone loss in murine and canine periodontal disease via recruitment of regulatory lymphocytes.Engaging adaptive immunity with biomaterialsCombinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheresStrategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease.Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.Combinatorial drug delivery approaches for immunomodulation.Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells.Positive Charge of "Sticky" Peptides and Proteins Impedes Release From Negatively Charged PLGA Matrices.Single and combined effect of retinoic acid and rapamycin modulate the generation, activity and homing potential of induced human regulatory T cells.Nanoparticulate delivery of agents for induced elastogenesis in three-dimensional collagenous matrices.TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.Cytokine Secreting Microparticles Engineer the Fate and the Effector Functions of T-Cells.The right touch: design of artificial antigen-presenting cells to stimulate the immune system
P2860
Q28080720-D4FF7C9B-0E75-49C0-8130-521220320664Q28547057-D72A584C-6F4F-4A5F-AC5E-A814188CA811Q35157382-CECC8D24-0492-466B-A386-B7103F596A15Q35661081-43100ACF-C77C-4C61-958A-90791B045DB9Q35998238-41502412-7692-40CE-BD45-8CE2F96BC0E0Q36011368-45F5E871-CD02-4A4C-B8E6-05B78570E637Q36379675-697BB010-8604-4355-98D1-85B78BD5C18AQ36703124-D7248583-DDB3-45B3-9C70-90475028221FQ37238282-EE392D21-61C4-42B1-B635-7819F586F87CQ37319692-CA948CBD-6821-4913-8915-A0641623B20BQ37691850-AF0BACA6-A112-4735-86A7-D79B4AB7A016Q37723891-91C7D704-5CC5-4108-855D-19A3E99C6824Q38253203-8CEC3358-329A-4F50-A5D4-F96BF8AABD6BQ38297557-FA7056CF-D575-4AAF-84E5-E2F760C3482AQ38680602-1AD2F59C-B97A-4D4A-B171-DE85D13FA848Q38874906-E45B119F-32EA-4B6B-BD73-2B4FCB78719CQ38994544-C1DEEA18-E55A-43CE-B124-835AFA9C0B58Q41137721-D5161D1D-3833-4CCA-A3F0-3C45E7D021DAQ46477159-7359115D-9E29-460D-837B-B0EEB5A7AB7EQ47138569-28D8EA05-CA17-4DD3-A422-FD31CB989060Q47189764-3821328E-C266-459B-BDA3-C951F9BF82AEQ58619853-DF44393B-6F71-4A62-893E-D42F1BB7470F
P2860
Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Controlled release formulation ...... duction of regulatory T cells.
@en
type
label
Controlled release formulation ...... duction of regulatory T cells.
@en
prefLabel
Controlled release formulation ...... duction of regulatory T cells.
@en
P2093
P2860
P50
P1476
Controlled release formulation ...... nduction of regulatory T cells
@en
P2093
Angus W Thomson
Eefje Dons
Erin E Nichols
Giorgio Raimondi
P2860
P356
10.1016/J.JCONREL.2012.01.013
P407
P577
2012-01-21T00:00:00Z